ADAM17 and gastric cancer: Another example of this is a trial withBortezomib, which interacts with the ADAM17 pathway, and hasbeen tried unsuccessfully in Phase II clinical trials in combination withpaclitaxel and carboplatin in metastatic patients with GC.71 As with the Lapatinib trial, this one had an overrepresentation of malepatients (89%) compared to female patients (11%).71 A common occurrence within many of the GC clinical trials is combinationof new therapies with paclitaxel or some type of Taxol.